Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,071
Total Claims
$1.5M
Drug Cost
924
Beneficiaries
$1,576
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+12%
Cost per patient vs peers
$1,576 vs $1,411 avg
+51%
Brand preference vs peers
16.0% vs 10.6% avg
Brand vs Generic
Brand: 3,188 claims · $1.1M
Generic: 16,725 claims · $305K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 254 | $162K |
| Rivaroxaban | 179 | $113K |
| Dapagliflozin Propanediol | 155 | $94K |
| Insulin Glargine,hum.Rec.Anlog | 245 | $84K |
| Apixaban | 122 | $82K |
| Linagliptin | 103 | $64K |
| Empagliflozin | 91 | $62K |
| Sitagliptin Phos/Metformin Hcl | 119 | $61K |
| Insulin Lispro | 116 | $44K |
| Levothyroxine Sodium | 706 | $44K |
| Sitagliptin Phos/Metformin Hcl | 66 | $36K |
| Semaglutide | 29 | $29K |
| Linagliptin/Metformin Hcl | 29 | $24K |
| Candesartan Cilexetil | 164 | $22K |
| Ticagrelor | 47 | $21K |
Prescribing Profile
Patient Profile
73
Avg Age
62%
Female
1.39
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data